- Massimo Calafiore begins as President and Chief Executive
Officer, effective immediately
- Julie Andrews is appointed as Chief Financial Officer, assuming
the role effective January 15, 2024
Orthofix Medical Inc. (NASDAQ: OFIX), a leading global spine and
orthopedics company, today announced that effective immediately,
Massimo Calafiore has assumed the role of President and Chief
Executive Officer (CEO) and as a member of the Orthofix Board of
Directors. In conjunction with Mr. Calafiore stepping into his role
as CEO, the Company has announced the appointment of Julie Andrews
as Chief Financial Officer. Ms. Andrews previously served as CFO
for Smart Wires Technology, where she led all finance, tax,
treasury, accounting, information technology, and investor
relations functions. Prior to that role, Ms. Andrews served as the
Senior Vice President, Global Finance for Wright Medical Group, a
global medical device company focused on extremities and biologics
that was acquired by Stryker in 2020, and before that, she was the
Vice President of Finance for the Spine and Biologics division of
Medtronic Inc.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240108827995/en/
Massimo Calafiore, President and CEO,
Orthofix Medical Inc. (Photo: Business Wire)
“I am thrilled to announce that Massimo has officially started
in his role as President and CEO and am equally excited to welcome
Julie to Orthofix as incoming CFO,” said Catherine Burzik, Chair of
the Board of Directors and former Interim CEO of Orthofix. “Our
search for these critical management roles was executed quickly and
thoroughly, with many highly qualified candidates expressing
interest in leading Orthofix. We are confident we have chosen two
visionary executives who will bring meaningful perspectives and
expertise to the Company and that their leadership will serve us
well in the years ahead.”
Mr. Calafiore commented, “I am honored to officially begin this
role at this important time for the Company, and I am excited to
welcome Julie to the team next week. I look forward to working with
the more than 1,600 employees who dedicate themselves to furthering
our mission to deliver meaningful and life-improving technologies
for our surgeon customers and their patients.”
About Massimo Calafiore
Mr. Calafiore joined LimaCorporate S.p.A., a global orthopedics
company in September 2022, where he served as CEO until the January
3, 2024, acquisition of LimaCorporate by Enovis Corporation (NYSE:
ENOV). Prior to this he served as Executive Vice President and
Chief Commercial Officer of NuVasive, Inc. During his tenure at
NuVasive, Mr. Calafiore served as President of NuVasive Specialized
Orthopedics (formerly Ellipse Technologies). Earlier in his career,
Mr. Calafiore worked for Waldemar Link GmbH & Co. KG and served
in various leadership roles across multiple business segments,
including orthopedics, lower extremities, and spine.
He received his M.Sc. in Mechanical Engineering from the
University of Catania and an MBA from New York University.
About Julie Andrews
Ms. Andrews joined Smart Wires Technology, a global transmission
grid technology company focused on enabling the transition to
renewable energy, as CFO in 2021. From 2012 to 2020, she served as
Senior Vice President, Global Finance and Vice President, Global
FP&A, and Chief Accounting Officer at Wright Medical Group,
where Ms. Andrews led a 170-person finance team. Prior to this, Ms.
Andrews spent many years in roles of increasing responsibility at
Medtronic Inc., including as Vice President of Finance for the
Spine and Biologics division, where she provided oversight of all
FP&A and accounting functions. Early in her career, Ms. Andrews
served as a Senior Financial Analyst for Thomas & Betts and as
an auditor for Thomas Havey, LLC.
Currently, she serves on the board of RxSight, Inc., an
ophthalmic medical device company. Ms. Andrews received a Bachelor
of Science in Accounting from Indiana University. She also
participated in advanced leader and director development programs
at both Medtronic and Wharton School of Business.
About Orthofix
Orthofix is a leading global spine and orthopedics company with
a comprehensive portfolio of biologics, innovative spinal hardware,
bone growth therapies, specialized orthopedic solutions, and a
leading surgical navigation system. Its products are distributed in
approximately 68 countries worldwide.
The Company is headquartered in Lewisville, Texas and has
primary offices in Carlsbad, CA, with a focus on spine and
biologics product innovation and surgeon education, and Verona,
Italy, with an emphasis on product innovation, production, and
medical education for orthopedics. The combined Company’s global
R&D, commercial and manufacturing footprint also includes
facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale,
CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany,
Paris, France and Sao Paulo, Brazil.
Forward-Looking Statements
This news release may include forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and Section 27A of the Securities Act of 1933, as
amended. In some cases, you can identify forward-looking statements
by terminology such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “projects,” “intends,”
“predicts,” “potential,” “continue” or other comparable
terminology. Orthofix cautions you that statements included in this
news release that are not a description of historical facts are
forward-looking statements that are based on the Company’s current
expectations and assumptions. Each forward-looking statement
contained in this news release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others: the ability of newly
launched products to perform as designed and intended and to meet
the needs of surgeons and patients, including as a result of the
lack of robust clinical validation; and the risks identified under
the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2022, which was
filed with the Securities and Exchange Commission (SEC) on March 6,
2023. The Company’s public filings with the Securities and Exchange
Commission are available at www.sec.gov. You are cautioned not to
place undue reliance on forward-looking statements, which speak
only as of the date when made. Orthofix does not intend to revise
or update any forward-looking statement set forth in this news
release to reflect events or circumstances arising after the date
hereof, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240108827995/en/
Media Relations Denise Landry DeniseLandry@orthofix.com
214.937.2529
Investor Relations Louisa Smith, Gilmartin Group
IR@orthofix.com
Orthofix Medical (NASDAQ:OFIX)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Orthofix Medical (NASDAQ:OFIX)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
